Abstract Details

Title Ocrelizumab treatment in patients with progressive multiple sclerosis: a single-center real-world experience

Topic Multiple Sclerosis

Presentation(s) MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 095

Objective

To provide first experience on progressive-MS (PMS) patients treated with Ocrelizumab (OCR) in a real-world setting.

Background

Real-word data on efficacy and adverse events (AE) of OCR in PMS are still scarce.

Design/Methods We collected safety and efficacy data from PMS patients treated with OCR at our MS Center (University of Genoa). The probability of disability-, relapse- and MRI activity-free survival/NEDA-3 status was calculated with Kaplan-Meier estimator and Cox proportional hazards regression analysis. AE were recorded.

Results We recorded data from 59 PMS patients [42 primary-progressive-MS (PPMS) and 17 secondary-progressive-MS (SPMS), 24 females, mean(SD) age 49.8(8.2) years] with mean disease duration (DD) of 12.1 (10.1) years, median (IQR) baseline EDSS: 5.5 (3.5-6.0) and median number of previous DMTs 1 (0-2). SPMS patients had longer DD (20.8vs8.6; p=0.004) and had mean ARR of 0.24 (0.4). 21 (36%) pts were treatment naive. Mean follow-up (FU) was 2.0 (1.1) years. 14 (24%) patients had an active MRI brain scan at baseline. At 1-year FU, MRI-inflammatory-activity-free survival was 87.3% (CI95%: 76.9-97.7%), relapse-free survival was 100% and progression-free survival was 82.7% (72.3-93.1%). NEDA-3 status was achieved in 72.3% (59.0-85.5%) of patients. No differences were noted between PPMS and SPMS. At multivariate analyses, no baseline characteristic was found be predictive of higher probability of progression-free survival, MRI-activity-free survival and NEDA-3 status. We recorded 69 AE in 36 pts (32 upper respiratory tract infections; 6 herpes simplex-1 reactivation; 7 lower urinary tract infections; 1 acute myeloid leukemia following myelodysplastic syndrome; 1 appendicitis treated with surgical procedure). No serious infusion-associated reactions were reported.

Conclusions We report short-medium term efficacy data in a real-world population of PMS patients treated with OCR, including a relatively high proportion of patients without MRI activity at baseline assessment. Our data suggest that OCR should be considered as treatment option in both patients with PPMS and SPMS.

Authors/Disclosures
Maria Cellerino, MD (University of Genoa) PRESENTER	Maria Cellerino has nothing to disclose.
Giacomo Boffa (Department of Neuroscience, University of Genova)	Mr. Boffa has nothing to disclose.
Caterina Lapucci, MD (DINOGMI, University of Genoa)	Dr. Lapucci has nothing to disclose.
	No disclosure on file
Nicolo Bruschi	Mr. Bruschi has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Alice Laroni	Alice Laroni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Alice Laroni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Alice Laroni has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Alice Laroni has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Alice Laroni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Alice Laroni has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Alice Laroni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. Alice Laroni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Alice Laroni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. The institution of Alice Laroni has received research support from Fondazione Italiana Sclerosi MUltipla . The institution of Alice Laroni has received research support from Ministero Salute. The institution of Alice Laroni has received research support from Ministero UNiversità.
Elisabetta Capello, MD (Ospedale San Martino - Clinica Neurologica)	No disclosure on file
Antonio Uccelli, MD (Ospedale S. Martino - Genova)	An immediate family member of Dr. Uccelli has received personal compensation for serving as an employee of Biogen. The institution of Dr. Uccelli has received research support from Merck. The institution of Dr. Uccelli has received research support from Roche.
	No disclosure on file
Matilde Inglese, MD, PhD (University of Genoa)	Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SANOFI GENZYME. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOGEN. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NOVARTIS. Dr. Inglese has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for MERCK-SERONO. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MS Journal.

��ɫ��

��ɫ��